Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
A high-density screen for linkage in multiple sclerosis.
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Substance Name: Amiloride
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Food and Drug Administration Approval Letter for Alemtuzumab
Prevention and treatment of MS: studying the effects of vitamin D.
Stress signaling etches heritable marks on chromatin.
Potassium-Retaining Diuretics: Amiloride
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Clinical profile of malay children with optic neuritis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Pages